Doctors prescribe Rinvoq (upadacitinib) to treat certain inflammatory conditions, such as rheumatoid arthritis (RA) and ulcerative colitis (UC). It’s available as an extended-release oral tablet and ...
Rinvoq (upadacitinib) is used to treat rheumatoid arthritis, Crohn’s disease, and many other inflammatory conditions. Rinvoq typically stays in your system for 2 to 3 days after your last dose. Rinvoq ...
NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily, for the treatment ...
After Novartis’ Pluvicto shook up iSpot.TV’s monthly rankings of the top TV advertising spenders in pharma to kick off the year, it was back to business as usual in February. AbbVie’s immunology ...
RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from the ...
AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...
For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA). The second replicate ...
NORTH CHICAGO, Ill., Aug. 21, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results